Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 106Neoplasms 14Neoplasm Metastasis 14Carcinoma, Non-Small-Cell Lung 4Advanced Breast Cancer 4Hereditary Sensory and Autonomic Neuropathies 3Recurrence 2Prostatic Neoplasms 2Ovarian Neoplasms 2Multiple Endocrine Neoplasia Type 1 2Endometrial Neoplasms 2Breast Neoplasms, Male 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Malignancies 1Recurrent Uterine Corpus Carcinoma 1Neoplasms by Site 1Lymphoma, Non-Hodgkin 1Lymphoma 1Locally Advanced (Inoperable) or Metastatic Breast Cancer 1Lethal Congenital Contracture Syndrome 2 1Hyperglycemia 1Hormone Receptor Positive HER-2 Negative Breast Cancer 1Hormone Receptor Positive Breast Cancer 1HER2-positive Breast Cancer 1Female Breast Carcinoma 1Exanthema 1

Interventions

trastuzumab biosimilar HLX02 1exemestane 1X-Rays 1Trastuzumab 1Taxes 1TVB-2640 1Specimen Handling 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1Magnetic Resonance Spectroscopy 1Letrozole 1Fulvestrant 1Disulfides 1CT-P6 1Biopsy 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Advanced Breast Carcinoma × Fulvestrant × Clear all
NCT03179904 2026-05-05

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Mayo Clinic

Phase 2 Active not recruiting
17 enrolled 10 charts
Breast

Advanced Breast Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡